CRSP · NASDAQ
CRISPR Therapeutics AG
$49.05 -0.60 (-1.19%)
Company overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 technology enables precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients with transfusion-dependent beta-thalassemia or severe sickle cell disease, in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $4.7B
- Employees
- 393
- Headquarters
- Zug
- Website
- crisprtx.com
- CEO
- Samarth Kulkarni
- Listed
- October 19, 2016
- P/E
- -7.89
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4.1M
- Gross profit
- -$220M
- Operating income
- -$550M
- EBITDA
- -$505M
- Net income
- -$569M
- EPS
- -$6.22
- Total assets
- $2.7B
- Total debt
- $788M
- Gross margin
- -5,360.86%
- Net margin
- -13,856.54%
- Earnings yield
- -12.68%
No geographic segmentation.
Showing FY 2025
CRSP
1D
NASDAQ
O50.14H51.05L49.36C49.99-0.51 (-1.01%)Vol906.11K